Monthly Archives: September 2017

Results from phase 2 CABOSUN trial of cabozantinib versus sunitinib for first-line treatment of advanced kidney cancer

By Sharon Kell|2017-09-11T10:50:14+00:0011 Sep 2017|Drug treatments|

Ipsen and Exelixis have announced updated results from the phase 2 [...]

Comments Off

Bristol-Myers Squibb stops combination immunotherapy clinical trial due to positive interim results

By Sharon Kell|2017-09-11T09:32:06+00:0011 Sep 2017|Uncategorized|

Bristol-Myers Squibb (BMS) has reported positive phase 3 results for its clinical [...]

Comments Off

A new drug to treat solid tumours

By Sharon Kell|2017-09-08T09:30:02+00:008 Sep 2017|Drug treatments|

The following blog from Mesothelioma.net gives a good summary of [...]

Comments Off

Combining radiotherapy with immunotherapy – a review of past, present and future developments

By Sharon Kell|2017-09-06T11:40:47+00:006 Sep 2017|Drug treatments|

New immunotherapy treatments are currently revolutionising the field of oncology [...]

Comments Off

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.

Registered charity in England, Wales (1164238), and Scotland (SC051330).

© Copyright Action Kidney Cancer 2021

Links

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org